Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $26
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the price target from $24 to $26.
Read original at benzingaStocks · News reference
HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $55
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $50 to $55.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 4:16 PM
- Checked
- Aug 17, 2026, 4:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37
BTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $28 to $37.
Read original at benzingaAlto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.73) by 10.96 percent. This is unchanged from the same period last year.
Read original at benzinga